Sign In
25 Nov 2014 13:56
Verona Pharma plc
("Verona Pharma" or the "Company")
Director's Dealing
25 November 2014, Cardiff - Verona Pharma plc (AIM: VRP) announces that further to the announcement of 24 November 2014 detailing the appointment of Dr. David Ebsworth as Non-Executive Chairman of the Board of Directors with effect from 1 December 2014, the Company was informed today that Dr. Ebsworth has purchased 1,326,667 Ordinary Shares at a price of 1.4 pence per Ordinary Share.
As a result Dr Ebsworth is now beneficially interested in 1,326,667 ordinary shares, representing 0.13% of the issued share capital.
-Ends-
For further information please contact:
Verona Pharma plc | Tel: +44 (0) 20 7863 3300 |
Jan-Anders Karlsson, CEO | |
N+1 Singer | Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer | |
FTI Consulting | Tel: +44 (0)20 3727 1000 |
Julia Phillips / Simon Conway |
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.
Follow the stocks
